ArticlePloS one2025
Rapid progression and short-term mortality during the January 2023 to July 2024 Cholera outbreaks in Zambia: A retrospective facility-based study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Factors associated with in-hospital mortality during the 2023 cholera outbreak in Hammanskraal, South Africa: a cross-sectional study.BMC infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholera remains one of the most rapidly fatal infectious diseases globally, with untreated cases leading to death within hours due to severe dehydration. Despite being preventable and treatable, it continues to pose a significant public health threat, especially in low and middle-income countries where water, sanitation, and hygiene (WASH) services are inadequate. This study aimed at investigating the rapid progression and short-term mortality during the January 2023 to July 2024 Cholera Outbreaks in Zambia. We conducted a retrospective cross-sectional study using national cholera surveillance data from Zambia's January 2023 to July 2024 outbreak to examine delays in care and associated outcomes. All suspected and confirmed cases with complete records on symptom onset, admission, and outcome were included. Key time intervals were calculated and analyzed using descriptive statistics and non-parametric tests, with subgroup comparisons by age, sex, and outcome status. Ethical approval was obtained, all data were anonymized, and analyses were performed using Stata version 14.2. A total of 3,655 cases were analyzed, of whom 52.2% were male and 37.8% were under 15 years. Nearly all patients (99%) were admitted as inpatients, and the overall mortality rate was 4.2%. The median time from symptom onset to death was 3 days, underscoring the rapid progression of the disease. Of the 3,655 cholera patients enrolled in the study, 2,162 patients were included in the survival analysis, the death rate was 0.85 per 100 person-days, with higher rates observed among males (1.05) and adults aged 50 years and above (2.71). Confirmed cases experienced the highest mortality, and survival probabilities were significantly lower among males (p = 0.0498), older adults (<0.0001), and confirmed cholera cases (<0.0001). Many cholera deaths in this outbreak happened within just a few days of admission, showing the need for quick assessment and urgent fluid treatment as soon as patients arrive. Older adults and men faced a higher risk of dying, which calls for triage protocols that pay closer attention to these groups. Laboratory confirmation was limited, with very few patients receiving rapid diagnostic tests, revealing a serious gap in surveillance and case management. Strengthening early warning systems, improving access to rapid tests, and focusing on high-risk groups are key steps to lowering deaths in future outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.